TABLE 1.
Datasets of SIV, SHIV, and HIV-1 transmission examined in the present study
| Source of infection | Dataseta | Viral doseb | Vaccination status | Route of transmissionc | Reference |
|---|---|---|---|---|---|
| Experimental | Keele-SIVsmE660 | Multiple low | Unvaccinated | i.r., i.v. | 9 |
| Experimental | Keele-SIVmac251 | Multiple low | Unvaccinated | i.r., i.v. | 9 |
| Experimental | Roederer-SIV control | Multiple low | DNA/Ad5 | i.r. | 6 |
| Experimental | Roederer-SIV mosaic gag | Multiple low | DNA/Ad5 Gag | i.r. | 6 |
| Experimental | Roederer-SIV mosaic Env | Multiple low | DNA/Ad5 mosaic Env | i.r. | 6 |
| Experimental | Roederer-SIV mac239 Env | Multiple low | DNA/Ad5 mac239Env | i.r. | 6 |
| Experimental | Klein-SHIV | Single high | Unvaccinated | Vaginal | 10 |
| Natural | pSF257-SHIV | NA | Unvaccinated | MSM | |
| Natural | Step-placebo-HIV | NA | Diluent vaccinated (no Ad5) | Unspecified | 7, 8 |
| Natural | Step-vaccine-HIV | NA | Ad5 gag-nef-pol vaccine | Unspecified | 7, 8 |
| Natural | Gnanakaran-HIV original FS2-FSC | NA | Unvaccinated | Unspecified | 15 |
| Natural | Gnanakaran-HIV holdout FS2-FSC | NA | Unvaccinated | Unspecified | 15 |
a
FS, Fiebig stage.
b
NA, not applicable.
c
i.r., intrarectal. i.v., intravenous.